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Concordance of pharmacist assessment with self-report scales to detect medication nonadherence during a medication review in homeless patients served at a mental-health clinic.
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ABSTRACT
Objective. To evaluate the concordance of the Modified Morisky Medication Adherence Scale (MMAS)
with a pharmacist assessment of medication adherence during a medication review in a group of patients
served by a homeless behavioral health clinic.
Methods. This was a retrospective study that examined the electronic medical records (EMR) of patients
≥18 years with a mental health and/or substance abuse diagnosis who received at least 1 medication
review by a pharmacist from October 2008 to September 2009 at a homeless behavioral health clinic in
Virginia. Patients had to have recorded responses to at least the first 4 questions of the 6-item MMAS to
be eligible for the study. The MMAS includes the following yes/no questions: Do you ever forget to take
your medicine? Are you careless at times about taking your medicine? When you feel better do you
sometimes stop taking your medicine? Sometimes if you feel worse when you take your medicine, do you
stop taking it? Do you know the long-term benefits of taking your medicine? Sometimes do you forget to
refill your prescription medicine on time? Pharmacists administered and recorded patient responses to the
MMAS at the beginning of the medication review. Responses were dichotomized into 2 categories,
adherent or non-adherent. In addition to the 6-item MMAS, adherence was calculated using the first 4 and
5 questions of the MMAS due to concerns about over or underestimation of non-adherence based upon
whether or not patients were aware of the long-term benefits of medications or did not forget to pick up
refills, but did not have transportation to do so. The pharmacist further assessed medication adherence by
asking probing questions about responses to the MMAS questions. A final pharmacist assessment of
adherence based upon these questions and information gathered during the medication review was
documented in the EMR. Sociodemographic information was also collected. Descriptive statistics were
calculated for all variables. The kappa statistic was used to assess the agreement between the variations of
the MMAS (6, 5, and 4 items) and the pharmacist assessment of medication adherence.
Results. A total of 288 patients were eligible for the study, which included 449 medication reviews. The
sample was 51.7% women, 60.4% African American, and had a mean (±SD) age of 44.8 (±10.1) years.
The majority (59.0%) received two or more medication reviews. Non-adherence was identified in 61.7%,
54.9%, and 49.7% of medication reviews using the 6, 5, and 4-item scales, respectively. The pharmacist
assessment determined non-adherence in 23.8% of medication reviews. Fair agreement was observed
between the 5 and 4-item scales (kappa statistic = 0.21 and 0.23, respectively) and the pharmacist
adherence assessment, whereas there was weak agreement between the 6-items and pharmacist
assessment (kappa statistic = 0.17).
Conclusion. The low agreement between the MMAS (6, 5, and 4-items) was unexpected and suggests
that the MMAS is not a good fit for assessing medication adherence in this population. For this
population, a combination of methods including self-report, pharmacist assessment and refill records,
when available, may provide the greatest insight into adherence.
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BACKGROUND
Medication adherence is defined as the extent to which patients take medications as prescribed by
their health care providers.1 In the United States, it is estimated that one-third to one-half of patients do
not adhere to medications as prescribed by their physician.2 Non-adherence to medications can lead to an
increased risk of hospitalizations, where an estimated one-third of hospital admissions related to adverse
drug events were due to non-adherence.3 Further, medication-related morbidity, including non-adherence,
is reportedly responsible for up to $290 billion (13%) of the total U.S annual health care expenditures.2
Several methods to measure adherence exist, yet there is no consensus on a “gold-standard” method.
Direct measures, such as measuring biologic fluid, help ensure medication is ingested, but can be
expensive, labor-intensive, and invasive.4 Indirect measures (pill counts, prescription refill data, and
electronic monitoring) are less invasive to the patient, but can be costly, time-consuming, and inaccurate.4
Self-report questionnaires, are an inexpensive and quick way to measure a patients’ adherence, but may
overestimate adherence due to patient recall and social desirability bias.4 Multiple self-report adherence
scales have been developed, including the Brief Medication Questionnaire (BMQ), Medication
Adherence Rating Scale (MARS), and Morisky Medication Adherence Scale (MAS).5 Each self-report
scale differs in its sensitivity and specificity, ease of clinical use and scoring, and validity among disease
states. A recent literature analysis of 5 self-report adherence scales found the Morisky MAS to be the
quickest to administer and simple for a clinician to score.5 Further, the MAS has been validated in
patients with hypertension, type 2 diabetes, dyslipidemia, and depression as a way to assess adherence.5-10
Despite their relative ease of use, self-report methods have not shown consistently high agreement with
other indirect measures of adherence. Several studies have reported on the concordance between indirect
adherence methods (pharmacy refill data, pill counts, and electronic monitoring) and self-report scales to
measure adherence with mixed results.11-14 These observed differences in agreement may be due to the
dissimilar disease states and self-report scales examined in each study.
Within the past decade, the development of medication therapy management (MTM) services has
created new opportunities for pharmacists. One of the 5 core elements of MTM service is medication
therapy review, which includes an assessment of medication adherence.15 Rickles and Svarstad reported
moderate to strong concordance between self-reported adherence from a modified BMQ and pharmacy
refill records for antidepressant medication.14 The authors also note that through the use of simple selfreport questions, a pharmacist can detect adherence problems early, and provide appropriate interventions
to improve adherence.14 To our knowledge, no data exists on how well self-report tools correspond with a
pharmacist’s assessment of medication adherence based upon information reported during a medication
therapy review. The goal of this paper will be to evaluate the concordance of patient’s self-reported
adherence using the 6-item Modified Morisky scale with a pharmacist’s assessment of adherence during a
medication review. Results of our study will be used to evaluate how a self-report scale may be used
during a pharmacist-provided medication review.

METHODS
This retrospective, cross sectional study examined the electronic medical records of patients who
received medication review by a pharmacist from October 2008 to September 2009. Eligibility criteria
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included: patients age 18 and older with a mental health and/or substance abuse diagnosis, received a
least one medication review by a pharmacist in the mental health clinic at a health care for the homeless
clinic, and had recorded responses to at least the first four questions (the original 4-item Morisky scale) of
the 6-item Modified Morisky scale.
Setting/Medication Review
All medication reviews took place in a federally funded health care for the homeless clinic located in
Richmond, Virginia. This health care clinic provides medical, dental, vision, mental-health, and case
management services to homeless or patients at risk of experiencing homelessness. Since 2005, the
health care clinic has had a community-academic partnership with the Virginia Commonwealth
University School of Pharmacy. 16 This partnership allows clinical faculty members of the school of
pharmacy to provide medication therapy review services to patients of the medical and mental-health
clinics. Medication review services are intended to assess the patient’s medication adherence and provide
education and/or interventions as necessary.16 Medication reviews begin with the pharmacist
administering a brief self-report questionnaire and documenting the patient’s answers in the electronic
medical record. The pharmacist also inquires about the patient’s use of OTC medications, herbal
supplements, caffeine, tobacco, alcohol, and illicit drugs. Pharmacists attempt to identify barriers to
adherence and examples of non-adherence by asking probing questions about medication taking behavior,
having the patients demonstrate how they take the medication, and engaging the patient to discuss any
difficulties they have related to the medication.
Scales and Scoring
The Case Management Society of America (CMSA) created a 6-item modified Morisky scale
(MMS) which included the original four questions of the Morisky MAS 4-item scale, plus two additional
questions to address persistence of taking medication. 17 This 6-item questionnaire measures two domains
of adherence; knowledge and motivation. 17 The World Health Organization’s 2003 report concerning
medication adherence listed motivation and knowledge as patient-related factors affecting adherence.18
Patients are categorized as having “high” or “low” knowledge and motivation based on their yes/no
response to each of the six questions of the MMS. 17 Patients are then assigned to one of 4 adherenceintention quadrants based on their scores of motivation and knowledge. This quadrant can be used to
identify deficiencies in knowledge and motivation and ultimately implement a plan to improve adherence.
17
Methods to improve a patient’s motivation and knowledge score include educating the patient on the
purpose of the medication, the disease state being treated, adverse side effects to be aware of, and
ensuring the patient understands how to take the medicine. The Case Management Adherence Guidelines
(CMAG) list pharmacists as a resource to educate patients about their medication and to reinforce
adherence. 17
At each medication review of our study, pharmacists administered and recorded patients’ responses
to the 6-item MMS. The use of the 6-item scale in this clinic was chosen over the 4-item MAS for its
ability to assess long-term medication adherence and its ease of use during patient interview. Although
the clinic in which this study took place does not use the 6-item scale to score adherence and classify
patients based on motivation and knowledge domains, as does the CSMA, we included this classification
in our analysis with pharmacist’s assessment of adherence for completeness.
6-item Scale (6-item MMS)

5
The 6-item MMS contains six questions in which patients respond yes or no. Each “no” response to
each question results in +1 (except question 5, in which a “yes” response would result in +1) and “yes”
responses to each question result in +0 (except question 5, where a “no” response would result in +0).
Scores for the 6-item MMS can range from 0 to 6, with higher scores indicating better adherence. The
CMSA further created 2 domains of adherence (knowledge and motivation) measured by the 6-item scale.
Questions 1,2, and 6 intend to assess a patient’s motivation for medication adherence, while questions 3,
4, and 5 reportedly assess a patient’s knowledge of the medication. Measuring these 2 domains are partly
influenced by the World Health Organization’s 2003 report concerning medication adherence listed
motivation and knowledge as patient-related factors affecting adherence.18 The motivation and knowledge
domain scores are obtained from the 6-item scoring. Patients are considered to have “high” motivation or
knowledge if they receive a score of ≥ 2 for each domain; patients with scores of ≤ 1 for each adherencedomain would be classified as “low” motivation or knowledge...
5-item Scale
The 5-item scale was developed from the 6-item scale by excluding question five, “Do you know the
long-term benefits of taking your medication…?”. Initially, our analysis was to include only the 6-item
scale, but in discussions with one of the pharmacists who conducted the medication reviews, we
hypothesized that patients may not know the long-term benefits of the medication, but still be adherent by
definition. The 5-item scale we created contained the same questions from the 6-item scale, excluding
question 5. This scale was scored similar to the 6-item, with each “no” response resulting in +1, and
“yes” responses +0. Scores could range from 0 to 5, with higher scores indicating better adherence.
4-itme Scale
Previously, we detailed how the 5–item scale was created by excluding question 5 of the 6-item
scale. Additionally, we thought to exclude question 6 of the 6-item scale, “Do you sometimes forget
refills?” due to the unique characteristics of our study population. Patients at this health care clinic must
present monthly to obtain refills for their medication. If patients were unable to attend an appointment
(due to lack of transportation, incarceration, hospitalization, or any reason), they were unable to obtain
medication refills. Patients with missed appointments were then considered to have “forgotten” refills,
when in truth, they were unable to maintain their appointment. The 4-item scale used is the original
Morisky MAS.6 The Morisky scale was first validated in assessing medication adherence in a population
of predominantly African-American women with hypertension.6 The original scale classifies patient’s
adherence as “high, medium, or low” based on the number of “yes” responses to each of the 4 questions.
Patients who answered, “yes” to 1 or 2 of the questions were identified as “medium adherence” and
patients who had answered, “yes” to 3 or 4 questions were classified as “low adherence”. Our analysis
scored the 4-item scale identically to the 5-item and 6-item scales, by awarding +1 for each “no” answer,
and +0 for each “yes” answer. Scores then ranged from 0 to 4, with higher scores indicating better
adherence. We chose to analyze agreement between pharmacist assessment of adherence with the 4-item,
5-item, and 6-item scales and examine how each scale compared.
Defining Non-Adherence
During medication review, pharmacists administered the 6-item MMS and had the opportunity to ask
the patient a series of questions regarding use of their medications. At the conclusion of the medication
review, pharmacists created a problem list, which may have included medication-related problems such as

6
ineffective dosing, duplication of medication therapy, and non-adherence. Patients in this study were
categorized as “non-adherent” by pharmacist assessment if non-adherence was noted in the problem list
generated at the conclusion of the medication review. All patients whose problem list did not include
non-adherence were considered “adherent” in this study.
Patients were considered non-adherent for each self-report scale if they scored ≥ 1. We chose to
dichotomize adherence into adherent/non-adherent categories to match the “non adherent/adherent”
classification used by pharmacist assessment. Additionally, a previous study had defined non-adherence
measured by the 4-item Morisky in the same way, when comparing self-report to electronic monitoring
(MEMS) data in patients taking tricyclic antidepressants. This group reported 84% sensitivity and 55.4%
specificity when non-adherence was defined as a score of ≥ 1 (a “yes” response to any question) on the 4item scale.10

ANAYLYSIS
Statistical analysis was conducted using SAS software. Descriptive statistics were used for all
sociodemographic and adherence variables. Kappa statistic with 95% confidence interval was used to
examine the agreement between pharmacist assessments of non-adherence with non-adherence defined by
self-report scales. Phi coefficient was used to examine the relationship between pharmacist assessment of
adherence and dichotomous levels of motivation/knowledge measured by the 6-item scale.

RESULTS
A total of 288 patients were eligible for this study, which included 449 medication reviews from
October 2008 to September 2009. The sample was 51.7% female, 60.4% African American, and had a
mean age of 44.8 ± 10.1 years. The mean number of mental health conditions was 2.3 ± 0.9 and the
mean number of medications at baseline was 3.5 ± 2.4. Nearly one-half of patients (45.8%) reported to
being homeless or doubling up with family or friends. The number of medication reviews ranged from 1
to 8, with a majority of patients (59%) receiving 2 or more medication reviews with a pharmacist. The
percentage of patients identified as non-adherent by each method of assessment are shown in table 1.
Non-adherence determined by pharmacist assessment was determined in nearly 24% of medication
reviews. Non-adherence determined by self-report scale seemed to increase as the number of self-report
questions increased. Table 2 shows data for non-adherence assessed by each method. Agreement
between pharmacist assessment of non-adherence and non-adherence by each self-report scale is reported
in table 3. Agreement was highest between pharmacist assessment and non-adherence determined by the
4-item Morisky scale, but showed only a fair correlation. Agreement between pharmacist assessment and
6-item scale showed the lowest agreement with a kappa value of 0.17, indicating weak agreement.
Although the 6-item scale is not used as described by the CMAG in our study population, we examined
the relationship between pharmacist’s assessment of adherence and levels of motivation/knowledge,
presented in table 4. Levels of both knowledge and motivation were found to be weakly related to
pharmacist assessment of adherence.
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DISCUSSION
This study examined the concordance of medication non-adherence assessed by a licensed
pharmacist with non-adherence detected by Morisky self-report scores. We found that the 4-item
Morisky, 5-item scale, and 6-item Modified Morisky, had fair to weak correlation with pharmacist
assessment of medication non-adherence. Agreement between pharmacist assessment and self-report
scale for determining non-adherence seemed to decrease as the number of self-report questions increased.
Regardless of the number of questions, self-report scales used in this study did not show high agreement
with pharmacist assessment. Our results show that pharmacist assessment detected the lowest proportion
of non-adherence (23.83%), while the 6-item scale predicted the highest proportion of non-adherence
(61.66%). Interestingly, the proportion of medication reviews determined non-adherent by 4-item
Morisky scale (49.67%) falls within the estimated value of non-adherence mentioned in the literature.1
The low non-adherence detected by pharmacists may be due to variation in pharmacist assessment.
Three different pharmacists conducted the medication reviews during the time period of this study. In
addition, each pharmacist may have had a different method of conducting medication review and
assessing non-adherence. Likewise, each pharmacist’s definition of non-adherence and/or the criteria by
which they classified non-adherence is likely to vary. It is also important to point out the criteria in which
we determined non-adherence assessed by pharmacist. Only patients with medication non-adherence
listed in the medication problem list were categorized as non-adherent in this study. We believe this
limitation, along with the variability in pharmacist assessment, may have lead to an underestimate of nonadherence when assessed by pharmacist. We also acknowledge several limitations that come from the use
of self-report scales to measure non-adherence. First, although the 4-item Morisky scale has been
validated in assessing medication adherence in several disease states, it has not been validated in
assessing medication adherence in mental health disorders. Previously it was mentioned that the 4-item
had been validated in assessing adherence to tricyclic antidepressants.10 It should be noted that TCAs
have largely been replaced by newer classes of antidepressants (SSRI/SNRI) to treat depression. Use of
the 6-item scale has limited data to suggest that it is validated in assessing medication adherence with any
class of medications.
An additional limitation of using any self-report scale is the reliability of patient’s response. Several
studies have shown that self-reported adherence is often overestimated.4,11-13 Our conservative definition
of non-adherence may be an additional limitation, and may have resulted in an overestimation of nonadherence assessed by self-report. George et al. (2000) reported a high sensitivity (84%) in
dichotomizing adherence by 4-item Morisky score (adherent = 0; non-adherent = ≥ 1) compared with
adherence measured by electronic monitoring (MEMS) data (adherence = 100% compliant; nonadherence = < 100% compliant). When the threshold for adherence, measured by MEMS data, decreased
to 90%, the calculated sensitivity also decreased to 75%.10 If we modify our definition of non-adherence
to answering “yes” to 2 or more questions on any self-report scale, we expect the proportion of
medication reviews determined non-adherent to decrease, with an expected decrease in sensitivity. As a
result, better agreement between pharmacist assessment and self-report may be observed, but with less
confidence in detecting true non-adherence. Modifying the definition of adherence to include patients
who are partially adherent, distorts the definition of adherence. Although each question of the self-report
questionnaire measures a certain aspect of adherence, each question of the self-report may not be equally
important at assessing adherence. Additionally, it is difficult to quantify a percentage of medication
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adherence that serves as a threshold for optimal outcomes. These limitations make the use of self-report
scales to difficult to incorporate into clinical practice.
Lastly, the use of the Morisky scale, or any self-report scale, in patients with mental-health disorders
who are homeless or at risk of homelessness may be invalid and/or unreliable. Patients with psychiatric
disorders are at an increased risk of non-adherence due to lack of insight, psychotic symptoms, and low
social functioning16. Additionally, psychiatric disease is highly prevalent among homeless persons, who
are at an increased risk for non-adherence due to high incidences of substance abuse, illiteracy, and lack
of health care access.16 These risk factors should be considered when choosing a method for assessing
medication adherence in this unique population.
When patients were categorized into levels of motivation and knowledge based on scores to the
6-item MMS, a patient’s level of knowledge or motivation showed a weak relationship to pharmacist
assessment of adherence. Although pharmacists in this study do not use the 6-item MMS to classify
patients based on knowledge and motivation, as described by the Case Management Adherence
Guidelines, we included this measure in our analysis. The 6-item scale was chosen for its ability to be
quickly administered during interview and its assessment of long-term benefits. Pharmacists desired a
scale that could assess a patients knowledge regarding the long-term benefits of medication adherence, as
certain mental-health medications may take up to 6 to 12 weeks to show effectiveness. The 6-item
Modified Morisky scale, as used in this study, may not be appropriate for simply identifying non-adherent
patients served at a health care for the homeless clinic.
The results of this study have several implications for improving the delivery of medication therapy
review by pharmacists. First, when multiple pharmacists are conducting medication reviews, a
standardized method for review may help eliminate variation in assessing adherence. Providing an initial
training on how medication reviews should be conducted may help improve the consistency by which
non-adherence is determined. One pharmacist in our study stated that they used the self-report
questionnaire as a way to follow up on areas of non-adherence highlighted by patient response to the selfreport questions. Also, it is imperative that all pharmacists involved in the medication review process
have a clear and unanimous definition of non-adherence. Perhaps most important is determining which, if
any, self-report questionnaire should be used. If a self-report questionnaire will be used, pharmacists
should agree upon which self-report to use and what its purpose will be. Lastly, if non-adherence is to be
measured by pharmacist’s assessment, it may be beneficial to include a dedicated area in the medical
record to categorize the patient as adherent or not. A simple box indicating adherent or non-adherent
would eliminate any ambiguity of having to interpret what was written in the note. Additionally,
including a free text area to specify what type of adherence barriers are suspected would be useful to other
clinicians when evaluating the patient at future visits.
Our study showed weak agreement between Morisky self-reports and pharmacist assessment. Better
agreement between pharmacist assessment of adherence may be seen if other indirect measures
(pharmacy refill data) are used in addition to self-reported adherence. Evaluating medication adherence
through indirect measures such as pharmacy refill data may not be appropriate or possible in this
population due to patients using multiple pharmacies, or obtaining medications in the form of samples
from prescribers. Self-report measures to detect non-adherence, by 3 versions of the Morisky scale, did
not show strong agreement with non-adherence assessed by a pharmacist during medication review.
Also, categories of high and low motivation/knowledge from the 6-item MMS were weakly related to
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pharmacist assessment. Self-report measures of adherence are considered by some to be inferior to other
indirect measures because of patient overestimates of adherence. However, in some circumstances, selfreport questionnaires may be useful to pharmacists as a fast, and inexpensive way to identify patients with
multiple barriers to adherence. Self-report scales may also be a useful way of engaging the patient to
discuss any adherence problems and allow the pharmacist to provide appropriate education and
interventions.
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Table 1: Number of medication review sessions identified as adherent or non-adherent from self-report
scores compared to pharmacist assessment.
Pharmacist Assessment
Adherent
Non-Adherent

12
4-item

5-item

6-item

Adherent
Non-Adherent
Adherent
Non-Adherent
Adherent
Non-adherent

198
144

28
79

N=342

N=107

177
162

24
83

N=339

N=107

151
188

20
87

N=339

N=107

N=226
N=223

N=201
N=245

N=171
N=275

Table 2: Non-Adherence rates as determined by method of assessment.
Non-Adherence (%)
23.83
49.67
54.93
61.66

Method of Detection
Pharmacist Assessment
4-item Self-Report
5-item Self-Report
6-item Self-Report

N
449
449
446
446

*Differences in number of medication reviews for analysis of the 5-item and 6item scales are due to incomplete self-report data for 3 medication reviews.

Table 3: Correlation between pharmacist assessment of adherence and 4-item, 5-item, and 6-item scales.
Method of Comparison
Pharmacists assessment
Motivation
Pharmacists assessment
Knowledge

N
446
449

Phi coefficient
0.19
0.20

Table 4: Relationship between pharmacist assessment of adherence and patient level of motivation and
knowledge.

Method of Comparison
Pharmacist assessment
4-item Morisky
Pharmacist assessment
5-item
Pharmacist assessment
6-item

N
449
446
446

Kappa statistic
0.23
0.21
0.17

